The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Selective elimination of BRCA1-deficient cells by inhibitors of poly(ADP-ribose) polymerase (PARP) is a prime example of the concept of synthetic lethality in cancer therapy. This interaction is counteracted by the restoration of BRCA1-independent homologous recombination through loss of factors such as 53BP1, RIF1, and REV7/MAD2L2, which inhibit end resection of DNA double-strand breaks (DSBs). To identify additional factors involved in this process, we performed CRISPR/SpCas9-based loss-of-function screens and selected for factors that confer PARP inhibitor (PARPi) resistance in BRCA1-deficient cells. Loss of members of the CTC1-STN1-TEN1 (CST) complex were found to cause PARPi resistance in BRCA1-deficient cells in vitro and in vivo. We show that CTC1 depletion results in the restoration of end resection and that the CST complex may act downstream of 53BP1/RIF1. These data suggest that, in addition to its role in protecting telomeres, the CST complex also contributes to protecting DSBs from end resection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684 · cited 2×
“The screening data were processed by the model-based analysis of genome-wide CRISPR-Cas9 knockout (MAGeCK) or the drugZ algorithm (Li et al., 2014; Wang et al., 2017), and the results were sorted on positive selected gene ranks to allow comparison across screens.”
MethodEasy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390 · cited 3×
“The polyclonal targeted populations were efficiently modified for the target site (Figures 2B–2D), as shown by TIDE (tracking of insertions or deletions [indels] by decomposition) analysis (Brinkman et al., 2014).”
MethodInfluentialDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · cited 1×
“…the BRCA-PARP paradigm might be extended beyond breast andovarian cancer because recent clinical studies indicate that a subset of prostate cancers harbor a homologous recombination (HR) defect and, hence, might benefit from ola- parib treatment (Mateo et al., 2015; Pritchard et al., 2016).”
BackgroundSelf-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064 · cited 2×
“The second PARPi resistance screen was performed in SpCas9-expressing Brca1 / ;Trp53 / mouse embryonic stem cells (mESCs) infected with a genome-wide lentiviral sgRNA library targeting 19,150 genes (Koike-Yusa et al., 2014).”
MethodBouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Self-citationTzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.079 · Cited by 761 · cited 2×
“SUM149PT cells expressing doxycy- cline-inducible SpCas9 were lentivirally infected with a genome-wide sgRNA library targeting 18,010 genes (Tzelepis et al., 2016).”
MethodDNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion
Celli, G. B., & de Lange, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1275 · Cited by 623
Miyake, Y., Nakamura, M., Nabetani, A., Shimamura, S., Tamura, M., Yonehara, S., Saito, M., & Ishikawa, F. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.009 · Cited by 350
53BP1, BRCA1, and the Choice between Recombination and End Joining at DNA Double-Strand Breaks
Daley, J. M., & Sung, P. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01639-13 · Cited by 318 · cited 1×
“…or RIF1, which antagonize resection to direct repair via NHEJ, and BRCA1, which promotes end resection to direct repair via HR (Chapman et al., 2013; Daley and Sung, 2014; Escribano-Dı́az et al., 2013; Feng et al., 2015; Cell Reports 23, 2107–2118, May 15, 2018 2111 (A and B) CTC1 depletion…”
Background
Cited by
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
The shieldin complex mediates 53BP1-dependent DNA repair
Noordermeer, S. M., Adam, S., Setiaputra, D., Barazas, M., Pettitt, S. J., Ling, A. K., Olivieri, M., Álvarez-Quilón, A., Moatti, N., Zimmermann, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0340-7 · Cited by 645
Self-citationEmran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Self-citationPARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Noordermeer, S. M., & van Attikum, H. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.008 · Cited by 456
Metadata
- Authors
- Barazas, M., Annunziato, S., Pettitt, S. J., de Krijger, I., Ghezraoui, H., Roobol, S. J., Lutz, C., Frankum, J., Song, F. F., Brough, R., Evers, B., Gogola, E., Bhin, J., van de Ven, M., van Gent, D. C., Jacobs, J. J. L., Chapman, R., Lord, C. J., Jonkers, J., & Rottenberg, S.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 23
- Issue
- 7
- Pages
- 2107-2118
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2803450780
- Cited by
- 155
- References
- 13
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. https://app.cochat.ai/papers/10.1016/j.celrep.2018.04.046
- The paper
- Barazas, M., Annunziato, S., Pettitt, S. J., de Krijger, I., Ghezraoui, H., Roobol, S. J., Lutz, C., Frankum, J., Song, F. F., Brough, R., Evers, B., Gogola, E., Bhin, J., van de Ven, M., van Gent, D. C., Jacobs, J. J. L., Chapman, R., Lord, C. J., Jonkers, J., & Rottenberg, S. (2018). The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. Cell Reports. https://doi.org/10.1016/j.celrep.2018.04.046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.